News: Keryx Biopharmaceuticals Inc (KERX.OQ)
KERX.OQ on NASDAQ Stock Exchange Capital Market
9.05USD
4:00pm EDT
9.05USD
4:00pm EDT
Price Change (% chg)
$-0.05 (-0.55%)
$-0.05 (-0.55%)
Prev Close
$9.10
$9.10
Open
$9.20
$9.20
Day's High
$9.28
$9.28
Day's Low
$8.79
$8.79
Volume
535,338
535,338
Avg. Vol
553,951
553,951
52-wk High
$9.98
$9.98
52-wk Low
$1.68
$1.68
Select another date:
Select another date:
- Keryx Biopharmaceuticals' CEO Discusses Q2 2013 Results - Earnings Call Transcript
- Here's What This $30 Billion Pension Fund Has Been Buying
- Cellceutix: Upcoming Significant Events And The Odds Of Success
- Keryx Biopharmaceuticals Presents An Attractive Investment Opportunity
- Significant Near Term Catalyst Should Further Rally Keryx Pharmaceuticals
- Keryx Biopharmaceuticals' Zerenex Likely To Receive FDA Approval
Press Releases
- Keryx Biopharmaceuticals to Present at The Oppenheimer & Co. Inc. 23rd Annual Healthcare Conference
- Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
- Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
- Keryx Biopharmaceuticals Initiates Phase 2 Study of Zerenex™ (ferric citrate) for the Treatment of Patients with Non-Dialysis Dependent Chronic Kidney Disease
- A Refreshing Outlook - Consensus Reports on Keryx Biopharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc.
- Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
- Keryx Biopharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
- Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
- Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results

